These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 14726177

  • 1. Neutralising antibodies against interferon beta in multiple sclerosis.
    Giovannoni G, Deisenhammer F.
    Lancet; 2004 Jan 10; 363(9403):166-7; author reply 168-9. PubMed ID: 14726177
    [No Abstract] [Full Text] [Related]

  • 2. Neutralising antibodies against interferon beta in multiple sclerosis.
    Mikol D.
    Lancet; 2004 Jan 10; 363(9403):167-8; author reply 168-9. PubMed ID: 14726179
    [No Abstract] [Full Text] [Related]

  • 3. Neutralising antibodies against interferon beta in multiple sclerosis.
    Antonelli G.
    Lancet; 2004 Jan 10; 363(9403):168; author reply 168-9. PubMed ID: 14726180
    [No Abstract] [Full Text] [Related]

  • 4. Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.
    Horowski R, Stürzebecher CS, Kapp JF.
    Funct Neurol; 2001 Jan 10; 16(2):117-28. PubMed ID: 11495417
    [No Abstract] [Full Text] [Related]

  • 5. Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis.
    Hemmer B, Stüve O, Kieseier B, Schellekens H, Hartung HP.
    Lancet Neurol; 2005 Jul 10; 4(7):403-12. PubMed ID: 15963443
    [Abstract] [Full Text] [Related]

  • 6. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis.
    Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N, Danish Multiple Sclerosis Study Group.
    Lancet; 2003 Oct 11; 362(9391):1184-91. PubMed ID: 14568740
    [Abstract] [Full Text] [Related]

  • 7. Use of interferon-beta in the treatment of multiple sclerosis.
    Derwenskus J, Lublin FD.
    Adv Neurol; 2006 Oct 11; 98():257-71. PubMed ID: 16400838
    [No Abstract] [Full Text] [Related]

  • 8. Development of resistance to biologic therapies with reference to IFN-β.
    Farrell RA, Marta M, Gaeguta AJ, Souslova V, Giovannoni G, Creeke PI.
    Rheumatology (Oxford); 2012 Apr 11; 51(4):590-9. PubMed ID: 22258390
    [Abstract] [Full Text] [Related]

  • 9. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.
    Farrell RA, Giovannoni G.
    Mult Scler; 2007 Jun 11; 13(5):567-77. PubMed ID: 17548434
    [Abstract] [Full Text] [Related]

  • 10. Interferon after 10 years in patients with multiple sclerosis.
    Pozzilli C, Prosperini L, Sbardella E, Paolillo A.
    Neurol Sci; 2006 Sep 11; 27 Suppl 5():S369-72. PubMed ID: 16998723
    [Abstract] [Full Text] [Related]

  • 11. [The formation and significance of antibodies to interferon beta during immunomodulating treatment of multiple sclerosis].
    Bartosik-Psujek H, Stelmasiak Z.
    Neurol Neurochir Pol; 2004 Sep 11; 38(1 Suppl 1):S53-6. PubMed ID: 15045868
    [Abstract] [Full Text] [Related]

  • 12. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis.
    Polman CH, Kappos L, Petkau J, Thompson A.
    J Neurol Neurosurg Psychiatry; 2003 Aug 11; 74(8):1162; author reply 1162-3. PubMed ID: 12876268
    [No Abstract] [Full Text] [Related]

  • 13. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.
    Rice G.
    Arch Neurol; 2001 Aug 11; 58(8):1297-8. PubMed ID: 11493173
    [No Abstract] [Full Text] [Related]

  • 14. Neutralising antibodies to interferon beta.
    Ortenzi C.
    J Neurol Neurosurg Psychiatry; 2003 Aug 11; 74(8):1162; author reply 1162-3. PubMed ID: 12876267
    [No Abstract] [Full Text] [Related]

  • 15. Beta-interferon for multiple sclerosis.
    Rudick RA, Goelz SE.
    Exp Cell Res; 2011 May 15; 317(9):1301-11. PubMed ID: 21396360
    [Abstract] [Full Text] [Related]

  • 16. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.
    Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS.
    Lancet Neurol; 2010 Jul 15; 9(7):740-50. PubMed ID: 20610349
    [Abstract] [Full Text] [Related]

  • 17. Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?
    Sorensen PS, Koch-Henriksen N, Bendtzen K.
    Mult Scler; 2007 Jun 15; 13(5):616-21. PubMed ID: 17548440
    [Abstract] [Full Text] [Related]

  • 18. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta.
    Lundkvist M, Greiner E, Hillert J, Fogdell-Hahn A.
    Mult Scler; 2010 Jul 15; 16(7):796-800. PubMed ID: 20534645
    [Abstract] [Full Text] [Related]

  • 19. Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now : Commentary to: 10.1007/s00415-010-5844-5 "One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients" by S. Malucchi et al.
    Menge T, Hartung HP, Kieseier BC.
    J Neurol; 2011 May 15; 258(5):904-7. PubMed ID: 21340521
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.